The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Heron Therapeutics Inc shares valued at $3,580,838 were purchased by Rubric Capital Management LP on Aug 08 ’25. At $1.50 per share, Rubric Capital Management LP acquired 2,387,225 shares. The insider’s holdings grew to 29,100,728 shares worth approximately $37.83 million following the completion of this transaction.
Also, Morgan Adam purchased 1,766,546 shares, netting a total of over 2,649,819 in proceeds. Following the buying of shares at $1.50 each, the insider now holds 8,753,290 shares.
As published in their initiating research note from H.C. Wainwright on June 09, 2025, Heron Therapeutics Inc [HRTX] has been a Buy and the price target has been revised to $6. Analysts at Rodman & Renshaw started covering the stock with ‘”a Buy”‘ outlook in a report released in mid June. As of April 23, 2024, CapitalOne has initiated its “an Overweight” rating for HRTX. Earlier on March 13, 2024, Needham resumed its rating. Their recommendation was “a Buy” for HRTX stock.
Analyzing HRTX Stock Performance
On last trading session, Heron Therapeutics Inc [NASDAQ: HRTX] rose 0.78% to $1.3. The stock’s lowest price that day was $1.25, but it reached a high of $1.3 in the same session. During the last five days, there has been a drop of approximately -7.14%. Over the course of the year, Heron Therapeutics Inc shares have dropped approximately -32.64%. Shares of the company reached a 52-week high of $2.6800 on 03/05/25 and a 52-week low of $1.1900 on 08/11/25.
Support And Resistance Levels for Heron Therapeutics Inc (HRTX)
According to the 24-hour chart, there is a support level at 1.2667, which, if violated, would cause prices to drop to 1.2333. In the upper region, resistance lies at 1.3167. The next price resistance is at 1.3333. RSI (Relative Strength Index) is 27.89 on the 14-day chart, showing oversold technical sentiment.
Is Heron Therapeutics Inc subject to short interest?
Stocks of Heron Therapeutics Inc saw a sharp steep in short interest on 2025-07-31 dropping by -1.67 million shares to 35.26 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 36.92 million shares. A decline of -4.73% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 32.04 of the overall float, the days-to-cover ratio (short ratio) decline to 32.04.
Which companies own the most shares of Heron Therapeutics Inc (HRTX)?
In terms of Heron Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 6 in the next 12 months, up nearly 365.12% from the previous closing price of $1.29. Analysts anticipate Heron Therapeutics Inc stock to reach 6 by 2025, with the lowest price target being 6. In spite of this, 2 analysts ranked Heron Therapeutics Inc stock as Buy at the end of 2025. On May 27, 2020, Guggenheim assigned a price target of “a Buy” to the stock and initiated coverage with a $24.
